Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression or death in certain patients with advanced breast cancer (ABC).
Lilly’s Phase III SERD breast cancer study has success in certain patients
The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and down so far as 43% when combined with Verzenio.
EMBER-3 Trial: Imlunestrant Plus Abemaciclib Improves Survival in Advanced Breast Cancer
Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, presents findings from the EMBER-3 trial evaluating imlunestrant for patients with advanced breast cancer.
Lilly reports positive Phase 3 breast cancer data for imlunestrant
Imlunestrant is being evaluated in patients with ER+/HER2- advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor. Ove
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Eli Lilly's Phase 3 EMBER-3 trial shows imlunestrant improves progression-free survival in advanced ER+ breast cancer patients with ESR1 mutations.
Imlunestrant offers new hope for ER-positive HER2-negative breast cancer
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;
Lilly Reports Positive Phase 3 EMBER-3 Study Data In Advanced Breast Cancer
Wednesday reported results from the Phase 3 EMBER-3 study of its drug candidate imlunestrant, in patients with advanced breast cancer. In the EMBER-3 study, estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients were randomized to receive imlunestrant alone,
healthday4h
SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations
For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...
emjreviews.com3h
Next-Gen SERD Improves Outcomes in Resistant Breast Cancer: SABCS 2024
Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...
The Pharma Letter6h
Lilly’s imlunestrant takes aim at oral SERD market
Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...
mskcc.org1d
Imlunestrant Stops Progression of ER+, HER2- Advanced Breast Cancer That Resists Standard Therapy
An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...
MedPage Today23h
Oral SERD Impresses in Advanced Breast Cancer With ESR1 Mutations
Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...
Next-generation treatment protects against progression in some patients with advanced breast cancer
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...